Ingalls & Snyder LLC Has $2.04 Million Holdings in Zoetis Inc (NYSE:ZTS)

Ingalls & Snyder LLC boosted its holdings in shares of Zoetis Inc (NYSE:ZTS) by 25.2% in the fourth quarter, HoldingsChannel reports. The fund owned 15,390 shares of the company’s stock after buying an additional 3,101 shares during the quarter. Ingalls & Snyder LLC’s holdings in Zoetis were worth $2,037,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Tarbox Family Office Inc. raised its stake in shares of Zoetis by 74.4% in the 3rd quarter. Tarbox Family Office Inc. now owns 218 shares of the company’s stock valued at $27,000 after acquiring an additional 93 shares in the last quarter. Prestige Wealth Management Group LLC bought a new position in Zoetis in the 2nd quarter worth approximately $27,000. Corbenic Partners LLC bought a new position in Zoetis in the 4th quarter worth approximately $31,000. Tradewinds Capital Management LLC bought a new position in Zoetis in the 3rd quarter worth approximately $31,000. Finally, Atlas Capital Advisors LLC bought a new position in Zoetis in the 3rd quarter worth approximately $33,000. Hedge funds and other institutional investors own 89.96% of the company’s stock.

In other news, CFO Glenn David sold 4,440 shares of Zoetis stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $120.02, for a total transaction of $532,888.80. Following the sale, the chief financial officer now owns 16,728 shares of the company’s stock, valued at approximately $2,007,694.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Roxanne Lagano sold 4,463 shares of Zoetis stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $118.99, for a total value of $531,052.37. Following the sale, the executive vice president now directly owns 33,190 shares in the company, valued at approximately $3,949,278.10. The disclosure for this sale can be found here. Insiders have sold a total of 123,917 shares of company stock worth $14,797,192 in the last three months. 0.29% of the stock is owned by insiders.

Several research analysts have commented on ZTS shares. Credit Suisse Group set a $138.00 price target on Zoetis and gave the stock a “buy” rating in a research report on Friday, October 11th. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $142.00 price target on the stock in a research report on Thursday, December 26th. Bank of America reaffirmed a “hold” rating and issued a $125.00 price target on shares of Zoetis in a research report on Thursday, December 5th. Raymond James started coverage on Zoetis in a research report on Thursday, January 9th. They issued a “market perform” rating on the stock. Finally, ValuEngine downgraded Zoetis from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Eight research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $127.47.

Shares of NYSE ZTS opened at $138.54 on Thursday. The company has a quick ratio of 3.02, a current ratio of 4.39 and a debt-to-equity ratio of 2.47. The business’s 50 day moving average is $128.82 and its two-hundred day moving average is $123.44. The company has a market cap of $64.57 billion, a P/E ratio of 44.26, a P/E/G ratio of 2.94 and a beta of 0.81. Zoetis Inc has a 12 month low of $82.26 and a 12 month high of $139.00.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.94 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.88 by $0.06. Zoetis had a return on equity of 70.78% and a net margin of 23.76%. The company had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.58 billion. During the same quarter last year, the firm earned $0.83 EPS. Zoetis’s revenue for the quarter was up 7.0% compared to the same quarter last year. Sell-side analysts expect that Zoetis Inc will post 3.6 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Friday, January 17th will be issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.58%. The ex-dividend date is Thursday, January 16th. This is a positive change from Zoetis’s previous quarterly dividend of $0.16. Zoetis’s dividend payout ratio (DPR) is presently 21.09%.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Story: 52-Week High/Low Prices For Stock Selection

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.